| CatalogCode: | NB100-134 |
| ProductName: | HIF-1 alpha Antibody |
| Product Description: | Rabbit Polyclonal anti-HIF-1 alpha |
| Clonality: | Polyclonal |
| Immunogen: | Fusion protein containing amino acids 432-528 of human HIF-1alpha. |
| Specificity: | This antibody is specific for HIF-1 alpha. |
| CrossReactivity: | Human, mouse and rat. Mouse results mixed. Other species have not been tested. |
| Packaging: | 0.1 ml Whole Rabbit antisera. |
| Uses: | This antibody is useful for ChIP, immunohistochemistry, and Western Blot. IHC applications have been mixed on mouse. |
| Localization: | Nucleus |
| Control: | PC12 nuclear extracts (hypoxically induced) and Cobalt Chloride treated Cos-7 nuclear extracts |
| Background: | Hypoxia contributes significantly to the pathophysiology of major categories of human disease, including myocardial and cerebral ischemia, cancer, pulmonary hypertension, congenital heart disease, and chronic obstructive pulmonary disease. HIF-1 is a nuclear protein involved in mammalian oxygen homeostasis. This occurs as a posttranslational modification by prolyl hydroxylation. HIF-1 is a heterodimer composed of HIF-1 alpha and HIF-1 beta subunits. Both subunits are constantly translated. However, under normoxic conditions, human HIF-1 alpha is hydroxylated at Pro402 or Pro564 by a set of HIF prolyl hydroxylases, is polyubiquinated, and eventually degraded in proteosomes. Under hypoxic conditions, the lack of hydroxylation prevents HIF degradation and increases transcriptional activity. Therefore, the concentration of HIF-1 alpha increases in the cell. In contrast, HIF-1 beta remains stable under either condition. HIF hydroxylases provide insight into hypoxic cell responses, which may be used to help isolate therapeutic targets. |
| Storage: | Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles. |
| Purity: | Whole antisera |
| Host_Name: | Rabbit |
| ListPrice: | 285 |
| NovusRef: | 1. Liu, X., et al. Hypoxia preconditioning of cardiomyocytes and cardioprotection: phophorylation of HIF-1 alpha induced by p42/p44 mitogen-activated protein kinases is involved. Pathophysiology. 00: 1-5 (2003). 2. Julie Litz and Geoffrey W. Krystal. Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1 activity and vascular endothelial growth factor expression in small cell lung cancer cells. Mol Cancer Ther. 5: 1415-1422 (2006). 3. Liao, D., et al. Hypoxia-Inducible Factor-1{alpha} Is a Key Regulator of Metastasis in a Transgenic Model of Cancer Initiation and Progression. Cancer Research 67: 563-572 (2007). 4. Bergeron, M., et al. Role of hypoxia-inducible factor-1 in hypoxia-induced ischemic tolerance in neonatal rat brain. Ann. Neurol. 48: 285-296 (2000). (Western blot, rat) 5. Harris, J. R., et al. Bone Marrow-Derived Cells Home to and Regenerate Retinal Pigment Epithelium after Injury. Investigative Ophthalmology and Visual Science 47: 2108-2113 (2006). 6. Harvey, A. J., et al. Regulation of Gene Expression in Bovine Blastocysts in Response to Oxygen and the Iron Chelator Desferrioxamine. Biol. Reprod. 77: 93-101 (2007). 7. Ietta, F., et al. Dynamic HIF1A Regulation During Human Placental Development. Biol. Reprod. 75: 112-121 (2006). 8. Lin, Q., et al. Differentiation Arrest by Hypoxia. J. Biol. Chem. 281: 30678-30683 (2006). 9. Wang, J., et al. Cytoprotective Effects of Hypoxia against Cisplatin-Induced Tubular Cell Apoptosis: Involvement of Mitochondrial Inhibition and p53 Suppression. J. Am. Soc. Nephrol. 17: 1875-1885 (2006). 10. Young, H. W. J., et al. Central Role of Muc5ac Expression in Mucous Metaplasia and Its Regulation by Conserved 5' Elements. Am. J. Resp. Cell Molec. Biol. 37: 273-290 (2007). 11. Kim J-w, Gao P, Liu Y-C, Semenza GL, Dang CV. Hypoxia-Inducible Factor 1 and Dysregulated c-Myc Cooperatively Induce Vascular Endothelial Growth Factor and Metabolic Switches Hexokinase 2 and Pyruvate Dehydrogenase Kinase 1. Mol Cell Biol. 2007 November 1, 2007;27(21):7381-93. 12. Sikder D, Kodadek T. The neurohormone orexin stimulates hypoxia-inducible factor-1 activity. Genes & Dev. 2007 November 15, 2007;21(22):2995-3005. 13. Singh RP, Gu M, Agarwal R. Silibinin Inhibits Colorectal Cancer Growth by Inhibiting Tumor Cell Proliferation and Angiogenesis. Cancer Res. March 15, 2008;68(6):2043-50. (immunohistochemistry) 14. Lauzier M-C, Robitaille GA, Chan DA, Giaccia AJ, Richard DE. BiPS, a matrix metalloprotease inhibitor, is a novel and potent activator of hypoxia-inducible factors. Mol Pharmacol. April 18, 2008:mol.108.045690. 15. Ohtomo S, Nangaku M, Izuhara Y, Takizawa S, Strihou CvYd, Miyata T. Cobalt ameliorates renal injury in an obese, hypertensive type 2 diabetes rat model. Nephrol Dial Transplant. April 1, 2008;23(4):1166-72. 16. Piantadosi CA, Suliman HB. Transcriptional Regulation of SDHa Flavoprotein by Nuclear Respiratory Factor-1 Prevents Pseudo-hypoxia in Aerobic Cardiac Cells. J Biol Chem. April 18, 2008;283(16):10967-77. 17. Zhang H, Bosch-Marce M, Shimoda LA, et al. Mitochondrial Autophagy Is an HIF-1-dependent Adaptive Metabolic Response to Hypoxia. J Biol Chem. April 18, 2008;283(16):10892-903. |
| AppSummary: | ChIP, IHC, WB |
| SpeciesSummary: | Hu, Mu, Mk, Rt |
| ALTnames: | anti-Hypoxia-inducible factor 1 alpha antibody, anti-HIF1 alpha antibody, anti-ARNT interacting proteinantibody, anti-Hif1a antibody, anti-ARNT interacting protein antibody, anti-HIF-1alpha antibody, anti-Hypoxia inducible factor 1 alpha antibody, anti-Hypoxia inducible factor 1 alpha subunit basic helix antibody |
| ProteinTarget: | HIF-1 alpha (Hypoxia-inducible factor 1 alpha) |
| PackageSize: | 0.1 ml |
| GeneralRef: | 1. Wang, G.L. and Semenza, G.L. Purification and Characterization of Hypoxia-inducible Factor 1. J. of Biol. Chem. 270(3): 1230-1237 (1995). 2. Semenza, G.L. Hypoxia-inducible factor 1 and the molecular physiology of oxygen homeostasis. J. Lab Clinical Medicine. 131: 207-214 (1998). 3. Kaelin, W.G. Many vessels, faulty gene. Nature. 399: 203-204 (1999). 4. Harvey, A.J., et al. Oxygen-Regulated Gene Expression in Bovine Blastocysts. Biol. Reprod. 71: 1108-1119 (2004). |
| NotesMain: | You may use COS-7 treated and untreated nuclear extracts for your positive and negative controls for hypoxic upregulation (NB 800-PC26) * The mobility of HIF-1 alpha induced by desferrioxamine or cobalt chloride treatment differs from the mobility of the hypoxia-induced protein. The reason is not known. |
order or
more information: | company product webpage |
| request information: |
|
|